Boceprevir: Phase III data

The double-blind, international Phase III HCV RESPOND-2 trial in 403 patients with chronic HCV genotype 1 infection who failed prior therapy with peginterferon and ribavirin showed that both regimens of boceprevir plus PegIntron peginterferon alfa-2b and Rebetol ribavirin met the primary endpoint of a significantly greater proportion of patients achieving an SVR vs. placebo plus PegIntron and Rebetol. Specifically, 66% and 59% of patients in the 48-week and response-guided treatment groups achieved an SVR, respectively, vs. 21% for placebo plus PegIntron and Rebetol (p<0.0001 for both). ...